[ET Net News Agency, 3 June 2025] Nomura raised the target price for Hansoh Pharma
(03692) to HKD25.64 from HKD19.86 and maintained the "neutral" rating.
The research house said it lifts FY25F/26F revenue by 4.5%/4.2% and revises up earnings
estimates by 10.4%/7.9%, respectively. (rc)